Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1269
Shown on this page
12
Current sort
Recently updated
Campus scope
Vanderbilt University Medical Center, Nashville, TN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Vanderbilt University Medical Center, Nashville, TN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1009–1020 of 1,269 matching trials with a site at Vanderbilt University Medical Center, Nashville, TN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Not applicable Interventional

Collaboration Oriented Approach to Controlling High Blood Pressure

NCT06124716
Site status not listed — check the official record
View directory record Official record
Conditions
Hypertension, Multiple Chronic Conditions
Interventions
Enhanced COACH CDS Tool, Usual Care COACH CDS Tool
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Columbia, Missouri • Portland, Oregon • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 9, 2026, 1:55 PM EST
Active, not recruiting Phase 3 Interventional

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

NCT03345823
Site status not listed — check the official record
View directory record Official record
Conditions
Crohn's Disease
Interventions
Upadacitinib, Placebo for Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
123
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 97 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 9, 2026, 1:55 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

NCT02205762
Site status not listed — check the official record
View directory record Official record
Conditions
Langerhans Cell Histiocytosis
Interventions
Prednisone, Vinblastine, mercaptopurine, INDOMETHACIN, Methotrexate, Cytosine Arabinoside, 2-chlorodeoxyadenosine, hematopoietic stem cell transplantation (RIC-HSCT), Intravenous immunoglobulin
Drug · Procedure · Biological
Lead sponsor
North American Consortium for Histiocytosis
Other
Eligibility
Up to 18 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 9, 2026, 1:55 PM EST
Active, not recruiting No phase listed Observational

MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.

NCT02075775
Site status not listed — check the official record
View directory record Official record
Conditions
Other Instability, Shoulder, Dislocations, Subluxations, Recurrent Dislocation of Shoulder Region
Interventions
Not listed
Lead sponsor
Carolyn M Hettrich
Other
Eligibility
12 Years to 99 Years
Enrollment
1,733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2042
U.S. locations
11
States / cities
San Francisco, California • Boulder, Colorado • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 9, 2026, 1:55 PM EST
Recruiting No phase listed Observational

Outcomes and Health Care Resource Utilization in Pediatric Congenital Heart Disease Patients Undergoing Non-Cardiac Procedures

NCT04604418
Status at this site: Recruiting
View directory record Official record
Conditions
Congenital Heart Disease in Children
Interventions
No intervention. It is observational
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 9, 2026, 1:55 PM EST
Recruiting Not applicable Interventional

Single Versus Dual Implant Fixation of Distal Femur Fractures

NCT06286670
Status at this site: Recruiting
View directory record Official record
Conditions
Articular Fractures
Interventions
Single Implant Fixation, Dual Implant Fixation
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 9, 2026, 1:55 PM EST
Active, not recruiting Phase 2 Interventional

Efficacy of Amicar for Children Having Craniofacial Surgery

NCT02229968
Site status not listed — check the official record
View directory record Official record
Conditions
Craniosynostosis
Interventions
Amicar (ε-aminocaproic acid), normal saline
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Months to 36 Months
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 9, 2026, 1:55 PM EST
Recruiting Not applicable Interventional

CPAP for the Treatment of Supine Hypertension

NCT05489575
Status at this site: Recruiting
View directory record Official record
Conditions
Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease, Supine Hypertension, Neurogenic Orthostatic Hypotension
Interventions
Active CPAP, Sham CPAP, Sleeping in a head-up tilt (HUT) position
Device · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 9, 2026, 1:55 PM EST
Active, not recruiting Phase 3 Interventional

A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS

NCT06144645
Site status not listed — check the official record
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
tVNS, intermittent stimulation, tVNS, continuous stimulation
Device
Lead sponsor
Foundation for Prader-Willi Research
Other
Eligibility
10 Years to 40 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
18
States / cities
Palo Alto, California • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Nov 9, 2026, 1:55 PM EST
Recruiting Not applicable Interventional

Deceased Donor Kidney Storage at 10 Celsius Versus Conventional Storage

NCT07385651
Status at this site: Recruiting
View directory record Official record
Conditions
End Stage Chronic Renal Failure, Chronic Kidney Disease (Stages 4 and 5), Kidney Transplantation Recipients
Interventions
10˚C deceased donor kidney storage using Traferox XPort
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Nov 9, 2026, 1:55 PM EST
Active, not recruiting Phase 2 Interventional

9-ING-41 in Patients With Advanced Cancers

NCT03678883
Site status not listed — check the official record
View directory record Official record
Conditions
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Interventions
9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan
Drug
Lead sponsor
Actuate Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Nov 9, 2026, 1:55 PM EST
Recruiting Phase 2Phase 3 Interventional

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

NCT06581406
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
RP2, Ipilimumab, Nivolumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
Not listed
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
29
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Nov 9, 2026, 1:55 PM EST

About this Vanderbilt University Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.